Two men in London just got six years apiece for pulling off a £1.3 million scam that hit the National Health Service right in its medicine chest.
Jignesh Patel, 46, and Rahil Patel, 42, were sentenced at Southwark Crown Court in October 2026 after a jury found them guilty of fraud by false representation and converting criminal property. They aren't related, and honestly, the mechanics of what they did are infuriatingly simple. They used over 1,600 fake prescriptions to get high-cost drugs reimbursed by the NHS—including medicines tied to leukaemia treatment—and then pushed that stock out through a wholesale business to buyers in Europe.
Most quick-hit news stories stop at the headline numbers and the prison term. That misses the real story. If you care about public healthcare, supply chain security, or how white-collar crooks game reimbursement systems, this case isn't just a courtroom headline. It's a case study in how a single operator can bridge retail dispensing and wholesale distribution to turn taxpayer money into cross-border profit.
How the £1.3m NHS cancer drug fraud actually worked on paper
On the surface, it looked like a classic double-dipping play with an international twist.
Jignesh Patel owned Wise Pharmacy on Fore Street in Edmonton, north London, alongside a pharmaceutical wholesale firm called Actipharm Limited. Rahil Patel worked there too, acting as a "Responsible Person" at Actipharm—a role that carries legal duties around record-keeping and proving where medicines actually come from.
Between 2015 and November 2017, investigators found that Wise Pharmacy processed 1,639 bogus prescriptions across 440 patient names and 24 GPs, adding up to 6,983 dispensed items. Prescribing doctors later confirmed there was no clinical documentation showing those patients needed the drugs or that the scripts had been written.
Seven high-cost medicines sat at the heart of the scheme: Sprycel (dasatinib), Noxafil (posaconazole), Atripla, Eviplera, Tobramycin, Truvada, and Viread. Notice what's going on there. Sprycel is a targeted leukaemia therapy, and Noxafil is a potent antifungal heavily used when immunocompromised patients—such as those undergoing blood cancer treatment—face severe fungal infections. Others on the list treat HIV or serious infections.
Normally, these expensive hospital-grade or tightly controlled treatments aren't routine high-street walk-ins. When a local community pharmacy suddenly claims huge volumes of them, red flags go up fast. Once the stock was pulled in, Actipharm sold medicines—including Sprycel and Noxafil—to pharmaceutical wholesalers in countries like Belgium, the Netherlands, Denmark, and Germany.
Text messages and missing paper trails
You don't need spycraft to catch people when they put their shortcuts in writing.
During the trial, prosecutors presented text messages between the two men that read like a blueprint of the operation. Messages included lines like "Drop the nox to the warehouse today," "U WANT MORE Sprycel N NOXA let me know asap," "Get me the scripts from the script guys," and "I got scripts".
That kind of casual phrasing doesn't leave much room for accidental paperwork errors. Even more telling, investigators found Actipharm selling Sprycel and Noxafil to other wholesalers despite lacking purchase records showing the wholesaler itself had bought them—pointing straight back to supply obtained via Wise Pharmacy.
Why warning signs took years to turn into convictions
Here's the part that frustrates anyone watching public spending: spotting an anomaly is one thing; proving a cross-border fraud case beyond reasonable doubt in a crown court takes years.
Local counter-fraud specialists traced claims back across clinical commissioning group areas including Barnet, Enfield, Newham, and Tower Hamlets. In 2016, NHS England issued an alert to north London pharmacies urging pharmacists to check directly with prescribing GPs on these high-cost items and noting it was unlikely community pharmacies would need to dispense them.
Yet even after reimbursement claims for Noxafil and Sprycel stopped following the alert, investigators found the medicines kept being acquired through false prescriptions—leaving hundreds of thousands of pounds worth of stock not claimed back through standard NHS reimbursement channels.
Why didn't the case wrap up overnight? Because medicine diversion doesn't stop at the borough border.
- Cross-border evidence takes time: Getting records from overseas wholesalers required formal legal channels, including European Investigation Orders submitted by the Crown Prosecution Service in November 2018 to authorities in the Netherlands, Germany, and Belgium, followed by work through Eurojust in The Hague and joint action with Danish police in Copenhagen in March 2020.
- Silence in interviews: When Jignesh Patel was arrested in December 2017—where police seized £190,000 in cash during property searches—and when Rahil Patel was interviewed under caution in February 2020, both gave "no comment" interviews.
- Complex financial and stock tracing: Investigators had to match prescription volumes, GP records, bank transfers, and wholesale invoices across multiple jurisdictions before a jury heard the case in autumn 2026.
Judge Cole didn't mince words at sentencing, calling the offending driven by greed with the two men acting as equal partners. For anyone following the case via the NHS Counter Fraud Authority, the six-year prison sentences—and upcoming confiscation proceedings under the Proceeds of Crime Act 2002—are meant to send a clear warning that cross-border diversion won't go unchallenged.
What this case reveals about medicine diversion and patient trust
Let's be real about the debate around parallel trade and medicine shortages. Legitimate pharmaceutical wholesaling across borders exists within regulated frameworks, and supply chains can get tight for all sorts of reasons—manufacturing hiccups, global demand shifts, or distributor bottlenecks.
That doesn't excuse turning public health budgets into a private arbitrage engine.
When high-cost medicines are drained out of a national system through fake prescriptions and sold abroad, two things get hurt at once. First, public money earmarked for patient care vanishes into criminal pockets. Second, even when a patient isn't directly handed a fake pill at the counter, any distortion in high-value stock availability adds friction to an already stretched healthcare system.
In my view, the biggest lesson isn't even the fake scripts themselves—it's the conflict of interest when one person controls both a dispensing pharmacy and a wholesale outlet handling the exact same high-margin drugs. Oversight rules like the "Responsible Person" regime exist on paper to guarantee accountability. When the same inner circle wears every hat, paper compliance can mask what's really moving out the back door unless data analytics and cross-check audits catch the mismatch early.
There's also a nuance worth keeping straight: news summaries often shorthand the whole basket as "cancer drugs," which grabs attention fast. Strictly speaking, the seven flagged medicines spanned leukaemia treatment, severe antifungal care, antiviral therapies, and antibiotics—all high-cost, high-scrutiny drugs, with Sprycel and Noxafil driving the biggest losses. Accuracy matters when talking about clinical care, and calling every drug on a seven-item list a cancer drug blurs how different clinical pathways work.
Practical steps to spot and report prescription or supply fraud
Whether you work in healthcare governance, run a pharmacy business, or simply want to know how to flag suspicious activity when you see it, you don't need to wait for a multi-year investigation to speak up.
- Audit high-cost, out-of-pattern dispensing immediately: If you manage pharmacy operations or compliance, review any spike in expensive hospital-typical or specialist medicines that don't match your local patient base or GP prescribing patterns.
- Enforce strict separation and verification on wholesale transfers: Never treat wholesale record-keeping as a formality. Verify batch origins, supplier invoices, and clinical legitimacy before moving high-value stock, especially when orders deviate from normal demand.
- Report suspicions early to counter-fraud teams: Patients, staff, and clinicians who spot unfamiliar prescriptions, strange billing queries, or questionable medicine movements can report concerns confidentially to the NHS Counter Fraud Authority or local counter-fraud specialists rather than brushing them off.
- Follow official recovery and regulatory updates: Watch for follow-on professional fitness-to-practise actions and Proceeds of Crime Act asset recovery steps if you track healthcare governance, since criminal sentencing is rarely the final chapter in large-scale public fraud cases.